Free Trial

HEALTHCARE: Viatris (VTRS Baa3/BBB-[N]/BBB): 2Q24 Results

HEALTHCARE

Credit neutral. On track to protect IG ratings, with spreads already close to low triple B averages.

  • Viatris reported revenue marginally ahead of consensus with 2% LfL growth.
  • Adj. EBITDA beat by 2%. We note litigation contingencies adjusted back in are around 11% of EBITDA.
  • FCF is close to consensus (2 estimates). Divestiture costs were a drag of $ 106mn, excluding that, at $426mn is around 9% lower YoY.
  • Divestiture program is now substantially completed. Gross leverage is steady from FY23 at 3.4x, on track for 3x target by FY24.
  • FY24 guidance lowered with revenues and EBITDA -2.5%, FCF -4% with higher expected SG&A costs.
  • Webcast replay https://event.choruscall.com/mediaframe/webcast.html?webcastid=GQI37vMH.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.